Late last year, Neuland completed the acquisition of an API/Intermediate manufacturing facility in Hyderabad – now designated Unit III.
The Unit III facility is spread across 12 acres and offers approximately 197KL of additional capacity, boosting Neuland’s overall API manufacturing capacity by about 40%. The multi-product facility, with five advanced intermediate & API production blocks, was inspected by the U.S. FDA in 2015. Unit III also provides on-site development, analytical method development, a quality control lab and a pilot plant.
With this new acquisition, Neuland now has three manufacturing facilities and one dedicated R&D center – all of which have been successfully inspected by the FDA (as well as other global regulatory agencies).
The launch of Unit III is very exciting for Neuland, and provides us with significantly increased operational flexibility to better meet the needs of our clients located in nearly 80 countries around the world.
Want to learn more? Contact us today.